About Decoy Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://salariuspharma.com/
Frequently Asked Questions
What is the 52-week range for DCOY?
The 52-week high is $55.92 and the 52-week low is $1.7911.
What is the P/E ratio for DCOY?
The P/E ratio data is currently unavailable.
What is the dividend yield for DCOY?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -315.23%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1042.83%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.71.
Analyst Recommendation Trends
Wall Street analyst consensus for DCOY over the last few months:
Latest DCOY News
The Small Cap Showcase Highlights 8 Public Companies at Their Investor Conference Today
NEW YORK, NY / ACCESS Newswire / October 1, 2026 / today will host eight micro and small cap public companies and a select audience of institutional and other qualified investors in New York City for a full day of company presentations, one on one meetings, and networking.The investor focused conference provides meaningful access to executive management teams and differentiated small cap investment opportunities.
Decoy Therapeutics to Present at The Small Cap Showcase
CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New YorkCAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across many viruses, today announced that Rick Pierce, Chief Executive Officer, will present at The Small Cap Showcase, taking place Thursday, October 1, 2026 in New York City. Mr. Pierce will deliv
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), today announced preclinical pharmacokinetic (PK) data supporting once-weekly intranasal administration for its lead program, DCOY-CoV. Results demonstrate that a single intranasal dose maintains therapeutic drug concentrations in both upper respiratory mucosal tissues and deep lung tissue for up to seven days.
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) shares moved
Unusual volume stocks in Wednesday's session
Volume analysis on 2026-09-23: stocks with an unusual volume in today's session.
Wednesday's session: top gainers and losers
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics (NASDAQ:VTGN) shares
Stay updated with the stocks that are on the move in today's pre-market session.
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Vistagen Therapeutics (NASDAQ:VTGN) shares increased by
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the Company's warrant inducement transaction.
/C O R R E C T I O N -- Decoy Therapeutics, Inc/
Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™) to target major respiratory and high consequence viral threats, today announced a refined corporate strategy to explore its D-MAVs for additional candidates, including a pan-filovirus program along the U.S. Food and Drug Administration (FDA) Animal Rule pathway for expedited regulatory approval. Based on recent encouraging discussions, the Company is actively pursuing non-dilutive go
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
Decoy Therapeutics, Inc. (NASDAQ: DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced its entry into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of the Series B Milestone Warrants to purchase shares of the Company's common stock, for a total of 1,184,4
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved upwards by
Decoy Therapeutics To Exercise 1,184,434 Series B Warrants At $3.25/Share for ~$3.85M; Cuts Series A & C Warrant Prices To $3.25 And Issues 2,368,868 New Warrants At $3.25/Share
Decoy Therapeutics, Inc. (NASDAQ:DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral
Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™) to target major respiratory and high consequence viral threats, today announced a refined corporate strategy to explore its D-MAVs for additional candidates, including a pan-filovirus program along the U.S. Food and Drug Administration (FDA) Animal Rule pathway for expedited regulatory approval. Based on recent encouraging discussions, the Company is actively pursuing non-dilutive go
Dow Gains Over 100 Points; AutoZone Posts Upbeat Earnings
U.S. stocks rose Tuesday: Dow +0.24%, Nasdaq +0.39%, S&P 500 +0.18%. Communication services led; energy fell. AutoZone beat earnings; oil dropped 2.4%.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. Greenland Mines (NASDAQ:GRML) shares rose 39.21% to
Decoy Therapeutics Announces Its Exploring Non-Dilutive Federal Grants, Public Health Collaborations To Support Preclinical, Clinical Development Of Biodefense Pipeline
Decoy Therapeutics, Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™) to target major respiratory and high consequence viral threats, today announced a refined corporate
Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Rick Pierce, Chief Executive Officer, to deliver an investor presentation on Thursday, September 10 in New YorkCambridge, Massachusetts--(Newsfile Corp. - September 8, 2026) - Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across many viruses, today announced that Rick Pierce, Chief Executive Officer, will present at the Moody Capital Solutions 2026 Disruptive Growth & Life...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-31 | Gauthier Patricia G. | +2,000 | - | - |
| 2026-08-31 | Marschel Peter Klaus | +3,900 | - | - |
| 2026-08-31 | Hibner Barbara Louise | +4,216 | - | - |
| 2026-08-31 | Burleson Tess | +2,000 | - | - |
| 2026-08-31 | McVicar William K. | +3,000 | - | - |
| 2026-08-31 | Lammers Paul | +2,000 | - | - |
| 2026-08-31 | Lieber Jonathan I | +2,000 | - | - |
| 2026-08-31 | Rosenblum Mark J | +9,682 | - | - |
| 2026-08-31 | HANISH ARNOLD C | +3,000 | - | - |
| 2026-08-31 | PIERCE FREDERICK II | +33,455 | - | - |